A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
379actual
Sites
74
Countries
Australia, Belgium, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-12-10 | actual | When the study began enrolling |
| Primary completion | 2020-06-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Endometrial Cancer
Interventions
- Drug: LY3484356 — also filed as Imlunestrant
- Drug: Abemaciclib — also filed as LY2835219
- Drug: Everolimus
- Drug: Alpelisib
- Drug: Trastuzumab
- Drug: Aromatase Inhibitor (AI)
- Drug: Pertuzumab
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities
measured Baseline through Cycle 1 (21/28 Day Cycle)
Publications
- PMID 41423595 — linked by the registry
- PMID 39241211 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed